Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC): A Patient Guide
At a Glance
H-ABC is a rare, progressive brain disorder caused by TUBB4A gene changes. It disrupts myelin and causes atrophy in the basal ganglia and cerebellum, leading to movement and developmental challenges. Diagnosis combines clinical findings, MRI, and genetic testing.
Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) is a rare, progressive neurological condition that belongs to the leukodystrophy family of disorders. It is caused by changes (pathogenic variants) in the TUBB4A gene, which provides the blueprints for a protein essential to the brain’s internal structure [1][2]. In H-ABC, these genetic changes disrupt the brain’s ability to adequately form myelin (the protective insulation around nerves), leading to inadequate myelin formation, or hypomyelination. At the same time, specific areas of the brain—the basal ganglia and the cerebellum—are associated with tissue loss, shrinking or undergoing atrophy over time [3][4]. This combination of challenges affects how the brain sends signals to the rest of the body, primarily impacting movement, balance, and developmental milestones.
The journey with H-ABC is unique for every child, but it typically follows a course marked by motor and developmental challenges that emerge in infancy or early childhood [5]. Parents often first notice delays in sitting, crawling, or walking, or changes in their child’s muscle tone [6]. Because the condition affects both the brain’s “wiring” (white matter) and its “control centers” (gray matter), children often experience a complex mix of movement disorders, including dystonia (involuntary contractions) and spasticity (stiffness) [7][8]. While some children may reach milestones and then experience a period of regression, the goal of care is always to maximize their functional abilities and maintain their comfort through every stage of the condition [9].
Diagnosis is confirmed through an integration of the clinical picture, characteristic imaging, and molecular genetic testing [10]. On an MRI, doctors look for the hallmark pattern of hypomyelination paired with the shrinking of the putamen and caudate (parts of the basal ganglia) and the cerebellum [11][12]. Because the brain is still developing in early childhood, when an early scan is ambiguous, repeat MRI may be useful to distinguish delayed myelination from hypomyelination, with the timing directed by a specialist [13]. Once a diagnosis is reached, the focus shifts toward assembling a multidisciplinary care team—a group of specialists including neurologists, therapists, and nutritionists—who can provide the comprehensive support needed to manage symptoms and prevent complications [14][15].
Living with H-ABC requires a proactive approach to symptom management, focusing on preserving quality of life and supporting the child’s ability to interact with the world. This includes dedicated physical and occupational therapy to maintain flexibility, as well as the use of communication technologies to ensure the child’s voice is heard [16][17]. While a diagnosis of H-ABC brings significant challenges, it also connects families to a global community of experts and researchers who are actively working to understand the TUBB4A gene and develop future therapies [18]. By focusing on coordinated care and symptomatic support, families can help their children live full, engaged lives while staying informed about the progress of modern science [14].
(Note: This guide is meant for education and does not replace the advice of your child’s medical team. Medical understanding evolves over time.)
In this guide
6 chapters
Understanding Your Child's H-ABC Diagnosis
Learn what your child's H-ABC diagnosis means: hypomyelination with basal ganglia and cerebellar atrophy, TUBB4A genetics, symptoms, care, and research.
Symptoms and the Path of Progression
Learn how hypomyelination with atrophy of basal ganglia and cerebellum progresses, including milestones, movement disorders, regression, and feeding concerns.
The Science of H-ABC: Genetics and Imaging
Learn how H-ABC is diagnosed through MRI patterns and TUBB4A testing, including hypomyelination, basal ganglia and cerebellar atrophy, and genetic counseling.
Managing Symptoms and Supporting Daily Life
Learn how H-ABC symptoms are managed, including dystonia, spasticity, feeding, breathing, seizures, scoliosis, hip health, and daily support for your child.
Building Your Care Team and Preparing for Visits
Learn how to build a multidisciplinary care team for H-ABC, prepare for specialist visits, gather MRI and TUBB4A records, and coordinate your child's care.
Daily Life: Safety, Communication, and Wellness
Learn how to support a child with H-ABC through safe therapy, communication tools, swallowing precautions, emergency red flags, and caregiver wellness.
Common questions in this guide
What causes H-ABC?
What are the early signs of H-ABC in a child?
How is H-ABC diagnosed?
What care and therapies can help a child with H-ABC?
What should families ask about monitoring H-ABC?
Are there clinical trials or research studies for H-ABC?
Get notified when new evidence is published on Hypomyelination with atrophy of basal ganglia and cerebellum.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
TUBB4A-related hypomyelinating leukodystrophy: New insights from a series of 12 patients.
Tonduti D, Aiello C, Renaldo F, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2016; (20(2)):323-330 doi:10.1016/j.ejpn.2015.11.006.
PMID: 26643067 - 2
Functional Investigation of TUBB4A Variants Associated with Different Clinical Phenotypes.
Xiao H, He H, Wu T, et al.
Molecular neurobiology 2022; (59(8)):5056-5069 doi:10.1007/s12035-022-02900-9.
PMID: 35668344 - 3
TUBB4A mutations result in specific neuronal and oligodendrocytic defects that closely match clinically distinct phenotypes.
Curiel J, Rodríguez Bey G, Takanohashi A, et al.
Human molecular genetics 2017; (26(22)):4506-4518 doi:10.1093/hmg/ddx338.
PMID: 28973395 - 4
TUBB4A mutations result in both glial and neuronal degeneration in an H-ABC leukodystrophy mouse model.
Sase S, Almad AA, Boecker CA, et al.
eLife 2020; (9()).
PMID: 32463361 - 5
The natural history of variable subtypes in pediatric-onset TUBB4A-related leukodystrophy.
Gavazzi F, Charsar B, Hamilton E, et al.
Molecular genetics and metabolism 2025; (144(3)):109048 doi:10.1016/j.ymgme.2025.109048.
PMID: 39951964 - 6
Longitudinal Evaluation of Cerebellar Signs of H-ABC Tubulinopathy in a Patient and in the taiep Model.
Alata M, González-Vega A, Piazza V, et al.
Frontiers in neurology 2021; (12()):702039 doi:10.3389/fneur.2021.702039.
PMID: 34335454 - 7
Therapeutic suppression of Tubb4a rescues H-ABC leukodystrophy.
Sase S, Hacker JL, Napit PR, et al.
Molecular therapy : the journal of the American Society of Gene Therapy 2026; (34(5)):2923-2943 doi:10.1016/j.ymthe.2026.01.016.
PMID: 41566774 - 8
[A report of atypical hypomyelinating leukodystrophy with atrophy of the basal ganglia and cerebellum caused by a de novo mutation in tubulin beta 4A (TUBB4A) gene and literature review].
Du Y, Li C, Guo J, et al.
Zhonghua nei ke za zhi 2017; (56(6)):433-437 doi:10.3760/cma.j.issn.0578-1426.2017.06.009.
PMID: 28592043 - 9
Acquisition of Developmental Milestones in Hypomyelination With Atrophy of the Basal Ganglia and Cerebellum and Other TUBB4A-Related Leukoencephalopathy.
Gavazzi F, Charsar BA, Williams C, et al.
Journal of child neurology 2021; (36(10)):805-811 doi:10.1177/08830738211000977.
PMID: 34514881 - 10
Hypomyelinating leukodystrophies - unravelling myelin biology.
Wolf NI, Ffrench-Constant C, van der Knaap MS
Nature reviews. Neurology 2021; (17(2)):88-103 doi:10.1038/s41582-020-00432-1.
PMID: 33324001 - 11
Auditory impairment in H-ABC tubulinopathy.
Lopez-Juarez A, Gonzalez-Vega A, Kleinert-Altamirano A, et al.
The Journal of comparative neurology 2021; (529(5)):957-968 doi:10.1002/cne.24990.
PMID: 32681585 - 12
A TUBB4A Met363Thr variant in pediatric hypomyelination without atrophy of the basal ganglia.
Hashiguchi M, Monden Y, Nozaki Y, et al.
Human genome variation 2022; (9(1)):19 doi:10.1038/s41439-022-00198-6.
PMID: 35661708 - 13
Rare forms of hypomyelination and delayed myelination.
Mura E, Parazzini C, Tonduti D
Handbook of clinical neurology 2024; (204()):225-252 doi:10.1016/B978-0-323-99209-1.00002-8.
PMID: 39322381 - 14
POLR3-Related Leukodystrophy: A Qualitative Study on Parents' Experiences With the Health Care System.
Le A, Thibault KA, Yazdani PA, et al.
Pediatric neurology 2025; (166()):81-87 doi:10.1016/j.pediatrneurol.2025.02.011.
PMID: 40106878 - 15
The Impact of RNA Polymerase III-Related Leukodystrophy on Nonaffected Family Members: A Qualitative Study.
Le A, Thibault KA, Yazdani PA, et al.
Pediatric neurology 2026; (176()):31-40 doi:10.1016/j.pediatrneurol.2025.12.004.
PMID: 41518854 - 16
Critical Functional Domains in Pediatric Onset TUBB4A-Related Leukodystrophy: A Clinical and Caregiver's Perspective.
Gavazzi F, Patel V, Erler JA, et al.
Pediatric neurology 2025; (173()):156-165 doi:10.1016/j.pediatrneurol.2025.09.019.
PMID: 41129987 - 17
Prescribing Assistive Technology: Focus on Children With Complex Communication Needs: Clinical Report.
Desch LW, Hobart-Porter LJ, Houtrow A,
Pediatrics 2025; (156(1)) doi:10.1542/peds.2025-072216.
PMID: 40518139 - 18
Generation of three induced pluripotent stem cell lines from individuals with late infantile TUBB4A-associated leukodystrophy caused by a c.1172G > A (p.R391H) de novo mutation in TUBB4A.
Hou Z, Gagne A, Cai J, et al.
Stem cell research 2026; (95()):104063 doi:10.1016/j.scr.2026.104063.
PMID: 42501571
This H-ABC guide is for informational purposes only and does not constitute medical advice. Your child's neurologist and multidisciplinary care team should interpret genetic results, MRI findings, and treatment choices for your child's situation.